(0.16%) 5 222.68 points
(0.32%) 39 513 points
(-0.03%) 16 341 points
(-1.34%) $78.20
(-2.13%) $2.25
(1.14%) $2 366.90
(0.11%) $28.40
(1.48%) $1 005.50
(0.11%) $0.928
(-0.30%) $10.83
(-0.01%) $0.798
(-0.42%) $92.15
3 days till quarter result
(bmo 2024-05-14)
Expected move: +/- 5.00%
@ $21.46
Issued: 10 May 2024 @ 15:27
Return: -0.40%
Previous signal: May 10 - 10:10
Previous signal:
Return: -0.90 %
Live Chart Being Loaded With Signals
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States...
Stats | |
---|---|
Today's Volume | 1.66M |
Average Volume | 2.35M |
Market Cap | 6.22B |
EPS | $0 ( 2024-02-06 ) |
Next earnings date | ( $0.290 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 32.88 |
ATR14 | $0.585 (2.74%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Garber Alan M | Buy | 23 491 | Common Stock |
2024-03-21 | Garber Alan M | Sell | 19 205 | Common Stock |
2024-03-21 | Garber Alan M | Sell | 23 491 | Option (right to buy) |
2024-02-23 | Peterson Amy C. | Buy | 82 121 | Common Stock |
2024-02-23 | Aftab Dana | Buy | 63 350 | Common Stock |
INSIDER POWER |
---|
27.73 |
Last 94 transactions |
Buy: 3 435 845 | Sell: 2 083 268 |
Volume Correlation
Exelixis Inc Correlation
10 Most Positive Correlations | |
---|---|
NVEI | 0.902 |
ARRW | 0.897 |
ARDX | 0.891 |
NBST | 0.891 |
LCYAU | 0.889 |
EBACU | 0.888 |
LCY | 0.886 |
RCII | 0.882 |
DAKT | 0.882 |
JNCE | 0.879 |
10 Most Negative Correlations | |
---|---|
GCBC | -0.91 |
SRCE | -0.895 |
GSBC | -0.895 |
HTBK | -0.887 |
ORPH | -0.886 |
BMRC | -0.885 |
SFST | -0.884 |
EQBK | -0.883 |
PTVE | -0.883 |
BWB | -0.883 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Exelixis Inc Correlation - Currency/Commodity
Exelixis Inc Financials
Annual | 2023 |
Revenue: | $1.83B |
Gross Profit: | $1.76B (96.04 %) |
EPS: | $0.650 |
FY | 2023 |
Revenue: | $1.83B |
Gross Profit: | $1.76B (96.04 %) |
EPS: | $0.650 |
FY | 2022 |
Revenue: | $1.61B |
Gross Profit: | $1.55B (96.41 %) |
EPS: | $0.570 |
FY | 2021 |
Revenue: | $1.43B |
Gross Profit: | $1.38B (96.32 %) |
EPS: | $0.733 |
Financial Reports:
No articles found.
Exelixis Inc
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators